Gilead Sciences, a U.S.-based biotechnology company, is deepening its U.K. presence with a new commercial headquarters in the heart of London from which to grow the company's portfolio, which includes treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular diseases and cancer. The company's presence in London will foster closer partnerships with clinicians, patient groups and National Health Service and government organizations, as Gilead continues its efforts to broaden access to innovative medicines.

The new London headquarters and expansions of its international operations in Uxbridge and U.K. R&D headquarters in Cambridge ​represent an increased investment in the U.K. of $19.6 million and a doubling of Gilead's U.K. workforce from 2013 to 2015, with 400 out of 600 U.K. employees based in London.

Gilead is joined in London by Boston-based Mobiquity, a mobile engagement company with clients including Pfizer, Merck, AbbVie and Weight Watchers. Attracted by London's strengths in digital health, Mobiquity is basing its $20 million European headquarters in the city. Early projects will include working with Pfizer to develop digital technologies that enable people to manage their own health, a key focus for the U.K.'s National Health Service. 

The new investment follows recent announcements by healthcare companies including Merck and Pfizer that they will establish or expand operations in London.